GlassScriptPhysician profile
Stacy James
NPI 1578163911
$5,268.34
in general payments reported to CMS, 2019-2025
26 companies · $912 in 2025
The $912 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $1,493 · 2023: $1,906 · 2024: $753 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Travel and Lodging: $254 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.60 |
| Travel and Lodging | $253.93 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $870.20 | 2024-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Abbvie INC. | $804.64 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $758.33 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.00 | 2021-2024 | Jardiance, Tradjenta, Ofev |
| Lilly USA, LLC | $473.34 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $333.53 | 2022-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $256.07 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $165.51 | 2022-2025 | |
| Astellas Pharma US INC | $116.90 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $95.69 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $90.45 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $85.89 | 2022-2025 | |
| Pfizer INC. | $74.43 | 2023-2024 | |
| Amarin Pharma, INC. | $66.63 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.85 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.66 | 2023-2024 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $37.88 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $36.99 | 2022-2024 | Rexulti |
| Exact Sciences Corporation | $36.97 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $35.47 | 2024 | Korlym |
| Sunovion Pharmaceuticals INC. | $25.52 | 2022 | |
| Boston Scientific Corporation | $22.02 | 2022 | |
| Averitas Pharma INC. | $18.72 | 2023 | Qutenza |
| Tactile Systems Technology INC | $18.00 | 2023 | Flexitouch Plus, Entre Plus |
| Lundbeck LLC | $14.52 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $14.13 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.